文献速递肝病消化道肿瘤与早癌

系统综述与荟萃分析:非肝硬化非酒精性脂肪性肝炎与其他肝病相比的肝细胞癌风险

Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases.
PubMed 文献 · Aliment Pharmacol Ther · 2018-08-22

该系统综述与荟萃分析纳入截至2016年4月的19项研究共168571名参与者,比较非肝硬化非酒精性脂肪性肝炎(NASH)与其他病因肝病患者的肝细胞癌(HCC)风险。非肝硬化NASH患者的HCC患病率为38.0%,其他病因非肝硬化患者为14.2%(P<0.001);非肝硬化NASH患者发生HCC的比值比高于其他病因非肝硬化患者(OR 2.61,95%CI 1.27-5.35,P=0.009)。在全部NASH患者(无论是否肝硬化)中,NASH作为基础肝病并未显著增加HCC风险(OR 1.43,95%CI 0.77-2.65,P=0.250)。

要点

  • 非肝硬化NASH患者HCC患病率为38.0%,其他病因非肝硬化患者为14.2%(P<0.001)。
  • 非肝硬化NASH患者发生HCC的比值比高于其他病因非肝硬化患者(OR 2.61,95%CI 1.27-5.35,P=0.009)。
  • 全部NASH患者(含肝硬化)HCC风险未显著增加(OR 1.43,95%CI 0.77-2.65,P=0.250)。

核心结论

  • 在非肝硬化受试者中,NASH患者相比其他病因肝病患者具有更高的HCC风险。
  • 需要进一步研究非肝硬化NASH患者中HCC的危险因素。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Scopus、Science Citation Index、AMED和Cochrane Library截至2016年4月的已发表研究。
  • 由两名独立评价者筛选文献并提取数据,计算随机效应比值比(OR)以获得NASH与非NASH组间效应量的合并估计。
  • 共纳入19项研究,168571名参与者,其中86%的纳入受试者患有肝硬化。

主要发现

  • 非肝硬化NASH的HCC患病率为38.0%;其他病因非肝硬化患者为14.2%(P<0.001)。
  • 非肝硬化NASH受试者发生HCC的比值比高于其他病因非肝硬化受试者(OR 2.61,95%CI 1.27-5.35,P=0.009)。
  • 在全部NASH受试者(无论是否肝硬化)中,NASH作为基础肝病未显著增加HCC风险(OR 1.43,95%CI 0.77-2.65,P=0.250)。

关键数值与推荐

  • 非肝硬化NASH的HCC患病率为38.0%,其他病因非肝硬化患者为14.2%(P<0.001)。
  • 非肝硬化NASH对比其他病因非肝硬化发生HCC的OR为2.61(95%CI 1.27-5.35,P=0.009)。
  • 全部NASH(含或不含肝硬化)对比其他病因的HCC风险OR为1.43(95%CI 0.77-2.65,P=0.250)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出缺乏长期前瞻性研究。
  • 原文结论提出需要进一步研究非肝硬化NASH患者中HCC的危险因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Given the lack of long-term prospective studies, it is challenging for clinicians to make informed decisions about screening and treatment decisions regarding the risk of hepatocellular carcinoma (HCC) in patients with non-alcoholic steatohepatitis (NASH) who do not have cirrhosis. AIM: To characterise the pooled risk of HCC in the non-cirrhosis population. METHODS: Published studies were identified through April 2016 in MEDLINE, Scopus, Science Citation Index, AMED and the Cochrane Library. Two independent reviewers screened citations and extracted data. Random effect odds ratios (OR) were calculated to obtain aggregate estimates of effect size between NASH and non-NASH groups. Between-study variability and heterogeneity were assessed. RESULTS: Nineteen studies with 168 571 participants were included. Eighty-six per cent of included subjects had cirrhosis. The prevalence of HCC in non-cirrhotic NASH was 38.0%; among other aetiologies in non-cirrhotics, it was 14.2% (P < 0.001). Non-cirrhotic NASH subjects were at greater odds of developing HCC than non-cirrhotic subjects of other aetiologies (OR 2.61, 95% CI 1.27-5.35, P = 0.009). When examining all NASH subjects either with or without cirrhosis, those with NASH as the underlying liver disease did not have a significantly increased risk of HCC (OR 1.43, 95% CI 0.77-2.65, P = 0.250). CONCLUSIONS: In non-cirrhotic subjects, those with NASH have a higher risk of HCC compared to other aetiologies of liver disease. Further study investigating the risk factors of HCC among non-cirrhotic NASH patients is needed.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Stine JG, Wentworth BJ, Zimmet A, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther. 2018. PMID: 30136293. doi:10.1111/apt.14937

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。